Company: BIAF
Filing Date: 2025-04-15
Form Type: DRS
Source: 0001641172-25-004915
Chunk: 16

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: DRS
Chunk 16
---
 certain other tax attributes may 
 be limited.                                                                              |

| ● | Our                                                                          
 Board can designate classes of Preferred Stock without stockholder approval. |

| ● | Provisions                                                                                 
 in our corporate charter documents and under Delaware law could make an acquisition of the 
 Company more difficult.                                                                    |

| ● | Provisions                                                                  
 in our Charter and Amended and Restated (“A&R”) Bylaws could make a merger, 
 tender offer, or proxy contest difficult.                                   |

| ● | Certain                                                                          
 provisions of Delaware’s General Corporation Law (“DGCL”) may have anti-takeover 
 effects.                                                                         |

| ● | Our                                                                                      
 Charter designates Delaware state or federal courts as the exclusive forum for disputes. |

| ● | Provisions                                                                                
 in our Charter and A&R Bylaws may discourage stockholders from bringing a lawsuit against 
 our directors and officers.                                                               |

| ● | Our                                                                        
 management collectively owns a substantial percentage of our Common Stock. |

| ● | If                                                                                         
 analysts publish unfavorable research, or none at all, about our business, our stock price 
 and trading volume could decline.                                                          |

| ● | Any                                                                                               
 inability to report and file our financial results accurately and timely could harm our business. |

| 4 |

<div align='center'>THE OFFERING</div>

The following summary contains basic information about this offering. The summary is not intended to be complete. You should read the full text and more specific details contained elsewhere in this prospectus.

| Common                                             
 Stock Offered                                      |     | Up                                                                                                                                         
 to [___] shares of Common Stock                                                                                                            |
| Pre-Funded                                         
 Warrants Offered                                   |     | We                                                                                                                                         
 are also offering to those purchasers, if any, whose purchase of shares of Common Stock in this offering would result in such purchaser,   
 together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser,       
 9.99%) of our outstanding Common Stock following the consummation of this offering, the opportunity to purchase, in lieu of the shares     
 of our Common Stock that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% (or, at the election               
 of the purchaser, 9.99%), Pre-Funded Warrants each to purchase one and one-half share of Common Stock at an exercise price of $0.007       
 per share. Each Pre-Funded Warrant is being issued together with one April 202